Treatment with pembrolizumab, an anti-PD-1 antibody, improved progression-free survival compared with investigator-choice chemotherapy in a phase II trial in patients with advanced-stage melanoma previously treated with ipilimumab. Two subsequent independent trials have confirmed that anti-PD-1 therapy is a better option than either chemotherapy or ipilimumab in the frontline setting.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Phototherapy techniques for the management of musculoskeletal disorders: strategies and recent advances
Biomaterials Research Open Access 28 November 2023
-
Enhanced anti-melanoma efficacy through a combination of the armed oncolytic adenovirus ZD55-IL-24 and immune checkpoint blockade in B16-bearing immunocompetent mouse model
Cancer Immunology, Immunotherapy Open Access 26 April 2021
-
Small-Molecule Targets in Tumor Immunotherapy
Natural Products and Bioprospecting Open Access 05 July 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734–1736 (1996).
Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
Freeman, G. J. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027–1034 (2000).
Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443–2454 (2012).
Hamid, O. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369, 134–144 (2013).
Robert, C. et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384, 1109–1117 (2014).
Ribas, A. et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 16, 908–918 (2015).
Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320–330 (2015).
Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521–2532 (2015).
Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Sullivan, R., Flaherty, K. Anti-PD-1 therapies—a new first-line option in advanced melanoma. Nat Rev Clin Oncol 12, 625–626 (2015). https://doi.org/10.1038/nrclinonc.2015.170
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2015.170
This article is cited by
-
Phototherapy techniques for the management of musculoskeletal disorders: strategies and recent advances
Biomaterials Research (2023)
-
Enhanced anti-melanoma efficacy through a combination of the armed oncolytic adenovirus ZD55-IL-24 and immune checkpoint blockade in B16-bearing immunocompetent mouse model
Cancer Immunology, Immunotherapy (2021)
-
Small-Molecule Targets in Tumor Immunotherapy
Natural Products and Bioprospecting (2018)
-
Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading
Cell Death & Disease (2017)
-
Immunoplasticity in cutaneous melanoma: beyond pure morphology
Virchows Archiv (2017)
